Progenics Pharmaceuticals, Inc. company was founded in 1986 and is based in Tarrytown, New York. Progenics Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases in the United States and internationally. The company, in collaboration with Wyeth Pharmaceuticals, provides RELISTOR-Subcutaneous injection for the treatment of opioid-induced constipation (OIC) in advanced illness patients receiving palliative care. It is also developing the HIV entry inhibitor, PRO 140, a humanized monoclonal antibody targeting the entry co-receptor, CCR5, and is in Phase II clinical testing; and a novel HCV entry inhibitor, PRO 206. In addition, Progenics Pharmaceuticals is conducting a Phase I clinical trial of a human monoclonal antibody-drug conjugate (ADC) designed to selectively target prostate-specific membrane antigen (PSMA), a protein found on the surface of prostate cancer cells, as well as in blood vessels supplying non-prostatic solid tumors; and various Phase I clinical trials with vaccines designed to treat prostate cancer by stimulating an immune response to PSMA.

Bayer AG is the management holding company for the Bayer Group. The Company’s business operations are organized into three subgroups: HealthCare, CropScience and MaterialScience, supported by the service companies Bayer Business Services, Bayer Technology Services and Currenta. Bayer HealthCare is involved in the research, development and manufacture of health products for people and animals. Bayer CropScience is engaged in the crop protection and non-agricultural pest control. Bayer MaterialScience supplies materials, such as polycarbonates and polyurethanes, and system solutions such as coatings, for a range of everyday uses. In October 2008, Bayer AG launched its new anticoagulant pill Xarelto in Britain and Germany, which has been granted approval in the European Union. The Company has subsidiaries operating in Europe, Asia-Pacific, North America, Latin America, Africa and Middle East. Bayer Schering Pharma AG became a wholly owned subsidiary of Bayer AG on September 25, 2008.

MethylGene's endeavors in the field of medicine may earn it a good look. The company is developing enzyme inhibitors to treat cancer and various infectious diseases. It develops product candidates for treatments for ailments such as solid tumors and hematological malignancies. MethylGene has also researched therapies to battle conditions including fungal infections and antibiotic resistance. The company forms licensing and collaboration agreements with other pharmaceutical firms to further its development programs.

StemCells, Inc. company was founded in 1988 and is based in Palo Alto, California. StemCells, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of cell-based therapeutics to treat damage to, or degeneration of, major organ systems. The Company has two product development programs: CNS Program, which is developing applications for its human neural stem cell and Liver Program, which is developing applications for its human liver engrafting cells. In addition, it is conducting preclinical work for spinal cord injury, myelin disorders and retinal disorders. In December 2008, the Company received authorization from the United States Food and Drug Administration (FDA) to initiate a Phase I clinical trial of its HuCNS-SC cells in a second indication, Pelizeaus-Merzbacher Disease (PMD), a fatal myelination disorder in the brain. In April 2009, StemCells, Inc. completed the acquisition of substantially all of the operating assets and liabilities of Stem Cell Sciences Plc.

Advanced Vision Research, Inc. company makes TheraTears, a line of over-the-counter eye drops developed to treat dry eye, a condition caused by aging, contact lens wear, sun, or wind. TheraTears are designed to imitate human tears, keeping eyes moist and allowing the surface of the eye to absorb oxygen and other needed nutrients. Other products include a TheraTears version for contact lens-wearers, an Omega-3-infused version to promote eye health, and an eyelid cleanser. Advanced Vision's products are made by Akorn's contract manufacturing unit and are sold through global retail outlets. TheraTears was developed by the late founder and former CEO Jeffrey Gilbard.

EraGen Biosciences, Inc. company is developing nucleic databases and other tools to help drug and diagnostics developers better use genomic information to streamline their R&D processes. Molecular clinical diagnostics, bioterrorism threat detection, and pesonalized medicine are other markets the company is pursuing. EraGen Biosciences has teamed with Luminex to distribute in vitro clinical diagnostics equipment that uses technology from both companies. Bayer HealthCare has licensed the company's MultiCode-PLx test for detecting cystic fibrosis.

Poniard Pharmaceuticals was founded in 1984 and is headquartered in South San Francisco, California. Poniard Pharmaceuticals, Inc., together with its subsidiary, NeoRx Manufacturing Group, Inc., focuses on the development and commercialization of oncology products for people with cancer. Its lead platform product candidate, Picoplatin, is a platinum-based cancer therapy that is designed to overcome platinum resistance associated with chemotherapy in solid tumors. Picoplatin is being studied in various cancer indications, combinations, and formulations. Poniard Pharmaceuticals is conducting a phase III clinical trial of intravenous picoplatin in small cell lung cancer; two phase II clinical trials in metastatic colorectal and castration-resistant (hormone refractory) prostate cancers; and a clinical trial of oral picoplatin in solid tumors. The company was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in June 2006.

Helicon Therapeutics is a development-stage biotechnology firm working on new therapies for memory loss and other cognition disorders. The company's research and development efforts focus on a protein that controls the signal pathway key to forming long-term memories. Scientists working for Helicon Therapeutics discovered the protein while studying the fruit fly genome. The company is working on drugs to not only maintain memory but also possibly to prevent memories from forming in the first place. Lead drug candidate HT-0712 has shown the ability to improve long-term memory in rats. Other candidates are in early stages of development.

Genzyme Biosurgery may turn you into the Six Million Dollar Man, but it can't do anything about your Six Million Dollar Medical Bill. The Genzyme Corp. division develops biotech products for orthopedic procedures. Top sellers include knee osteoarthritis treatment Synvisc and Carticel, which repairs damaged knee cartilage. Genzyme Biosurgery's biosurgical specialties unit makes Seprafilm, which prevents tissue adhesions after surgery. Other products include those to assist in adhesion prevention and hernia repair (Sepramesh) and severe burn treatment (Epicel).

ZARS Pharma, Inc. operates as a specialty pharmaceutical company that focuses on developing and commercializing topically administered drugs using its proprietary drug delivery technologies, primarily in the area of pain management. It is developing a portfolio of proprietary products and product candidates based on its Controlled Heat-Assisted Drug Delivery and phase-changing cream technologies. The company’s products include Pliaglis, a topical anesthetic cream for dermal anesthesia prior to painful cosmetic procedures, such as laser surgery and dermal filler injections; and Synera, a topical patch for providing dermal analgesia for potentially painful superficial procedures, such as venous access procedures involving needles and immunization injections of children. Its products also comprise ThermoProfen, which is entering into Phase 3 clinical trials for the treatment of mild to moderate chronic pain associated with osteoarthritis of the knee; and Ketoprofen DuraPeel, a Phase 1 clinical trial product for the treatment of acute musculoskeletal pain resulting from soft tissue injuries, such as muscle strains, ankle sprains, and sports injuries. In addition, the company is developing the Alprazolam Patch, which is in Phase 1 clinical trial, for the treatment of panic disorder. The company was formerly known as ZARS, Inc. and changed its name to ZARS Pharma, Inc. in July, 2007. The company was founded in 1996 and is based in Salt Lake City, Utah.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.